Chongqing Pharscin Pharmaceutical Co Ltd
SZSE:002907
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Chongqing Pharscin Pharmaceutical Co Ltd
Operating Income
Chongqing Pharscin Pharmaceutical Co Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Chongqing Pharscin Pharmaceutical Co Ltd
SZSE:002907
|
Operating Income
¥72.4m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Operating Income
¥6.6B
|
CAGR 3-Years
37%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Operating Income
¥9B
|
CAGR 3-Years
42%
|
CAGR 5-Years
6%
|
CAGR 10-Years
13%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Operating Income
¥4.8B
|
CAGR 3-Years
13%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Operating Income
¥7.8B
|
CAGR 3-Years
22%
|
CAGR 5-Years
13%
|
CAGR 10-Years
35%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Operating Income
¥3.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
203%
|
CAGR 10-Years
N/A
|
|
Chongqing Pharscin Pharmaceutical Co Ltd
Glance View
Chongqing Pharscin Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of chemical and Chinese medicine. The company is headquartered in Chongqing, Chongqing and currently employs 1,467 full-time employees. The company went IPO on 2017-10-20. The firm operates three segments: Pharmaceutical Industry segment, Commercial Circulation segment and Retail segment. The firm's products are categorized into the pharmaceuticals of digestive system, nervous system, otorhinolaryngology, cardiovascular and cerebrovascular systems and immune systems. The Company’s products include Weidimei (aluminum carbonate tablets), Ganju Bingmei Tablets, Bawei Qilong Particles, Liuwei Anshen Capsules, Sodium Ferulate for Injection, Omeprazole Sodium for Injection and Gabexate Mesilate for Injection. The firm mainly distributes its products in domestic market.
See Also
What is Chongqing Pharscin Pharmaceutical Co Ltd's Operating Income?
Operating Income
72.4m
CNY
Based on the financial report for Sep 30, 2025, Chongqing Pharscin Pharmaceutical Co Ltd's Operating Income amounts to 72.4m CNY.
What is Chongqing Pharscin Pharmaceutical Co Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
-14%
Over the last year, the Operating Income growth was -2%. The average annual Operating Income growth rates for Chongqing Pharscin Pharmaceutical Co Ltd have been -7% over the past three years , -14% over the past five years .
